Phase 3 breast can­cer fail­ure leads to staff cuts, stock drop at G1 Ther­a­peu­tics

G1 Ther­a­peu­tics said its lung can­cer drug Cosela didn’t fare bet­ter than a place­bo in ex­tend­ing the lives of breast can­cer pa­tients.

In the Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.